Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

被引：2

作者：

Phillips, Tycel ^{[1
]}

Avigdor, Abraham ^{[2
,3
]}

Gurion, Ronit ^{[4
,5
]}

Patti, Caterina ^{[6
]}

Corradini, Paolo ^{[7
]}

Tani, Monica ^{[8
]}

Mehta, Amitkumar ^{[9
]}

Lossos, Izidore S. ^{[10
]}

Zinzani, Pier Luigi Luigi ^{[11
]}

Thieblemont, Catherine ^{[12
]}

Jurczak, Wojciech ^{[13
]}

Zheng, Fred ^{[14
]}

Rappold, Erica ^{[14
]}

Zhao, Wanying ^{[14
]}

Johnson, Peter

机构：

[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[2] Inst Hematol, Sheba Med Ctr, Ramat Gan, Israel

[3] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

[4] Rabin Med Ctr, Inst Hematol, Petch Tikva, Israel

[5] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[6] Azienda Villa Sofia Cervello, Div Oncohematol, Palermo, Italy

[7] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[8] Osped Ravenna, Azienda Unita Sanitaria Locale Romagna, Ravenna, Italy

[9] Univ Alabama Birmingham, Div Hematol Oncol, Dept Med, Birmingham, AL USA

[10] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[11] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[12] Univ Paris, Hop St Louis, AP HP, Hematooncol DMU DHI, Paris, France

[13] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[14] Southampton Gen Hosp, Canc Res UK Ctr, Southampton, Hants, England

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-147778

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：7

共 50 条

[1] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Phillips, Tycel J.
Corradini, Paolo
Gurion, Ronit
Patti, Caterina
Tani, Monica
Avigdor, Abraham
Jurczak, Wojciech
Mehta, Amitkumar
Zinzani, Pier Luigi
Lossos, Izidore S.
Thieblemont, Catherine
Zheng, Fred
Rappold, Erica
Zhao, Wanying
Johnson, Peter
[J]. BLOOD, 2020, 136
[2] A phase 2 study of the PI3K5 inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
Phillips, Tycel J.
Avigdor, Abraham
Gurion, Ronit
Patti, Caterina
Corradini, Paolo
Tani, Monica
Mehta, Amitkumar
Lossos, Izidore S.
Zinzani, Pier Luigi
Thieblemont, Catherine
Jurczak, Wojciech
Zheng, Fred
Rappold, Erica
Zhao, Wanying
Jiang, Ping
Johnson, Peter
[J]. BLOOD ADVANCES, 2024, 8 (04) : 867 - 877
[3] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)
Lynch, Ryan C.
Avigdor, Abraham
McKinney, Matthew S.
Paneesha, Shankara
Wahlin, Bjorn
Hrom, John S.
Cunningham, David
Morley, Nicholas
Canales, Miguel
Bastos-Oreiro, Mariana
Belada, David
Devizzi, Liliana
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
[J]. BLOOD, 2021, 138
[4] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
[5] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Lynch, Ryan C.
Paneesha, Shankara
Avigdor, Abraham
McKinney, Matthew S.
Wahlin, Bjorn E.
Hrom, John S.
Belada, David
Canales, Miguel
Cunningham, David
Devizzi, Liliana
Morley, Nicholas
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Trneny, Marek
[J]. BLOOD, 2020, 136
[6] Efficacy and Safety of Parsaclisib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated With a BTK Inhibitor: Primary Analysis From a Phase 2 Study (CITADEL-205)
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 11 - 13
[7] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)
Mehta, Amitkumar
Trneny, Marek
Walewski, Jan
Ribrag, Vincent
Dartigeas, Caroline
Christensen, Jacob Haaber
Pane, Fabrizio
Rodriguez, Guillermo
Taszner, Michal
Venugopal, Parameswaran
Zilioli, Vittorio Ruggero
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Zinzani, Pier Luigi Luigi
[J]. BLOOD, 2021, 138
[8] SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)
Tedeschi, A.
Trotman, J.
Zinzani, P.
Cavallo, F.
Marasca, R.
Liberati, A.
Linton, K.
Mckay, P.
Hu, B.
Coleman, M.
Ardeshna, K.
Bijou, F.
Marcus, R.
Portell, C.
Thieblemont, C.
Bachy, E.
Costello, R.
Iyengar, S.
Mocikova, H.
Co, M.
Li, X.
Zhou, W.
Cappellini, M.
Tankersley, C.
Huang, J.
Opat, S.
[J]. HAEMATOLOGICA, 2021, 106 (10) : 35 - 35
[9] Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study
Hamadani, Mehdi
Coleman, Morton
Boccia, Ralph
Duras, Juraj
Hutchings, Martin
Zinzani, Pier Luigi
Cordoba, Raul
Oreiro, Mariana Bastos
Williams, Vanessa
Liu, Huiqing
Stouffs, Michael
Langmuir, Peter
Sancho, Juan-Manuel
[J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 (05) : 848 - 857
[10] Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)
Zinzani, Pier Luigi
Delwail, Vincent
Paneesha, Shankara
Rule, Simon
Garcia-Sancho, Alejandro Martin
Marin-Niebla, Ana
Salles, Gilles
Sancho, Juan-Manuel
Vergote, Vibeke
Zilioli, Vittorio Ruggero
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Mehta, Amitkumar
[J]. BLOOD, 2020, 136

← 1 2 3 4 5 →